NDA 022308 · Bausch and Lomb
Besivance
Besifloxacin Hydrochloride · Ophthalmic · Quinolone Antimicrobial
NovelLast checked: Nov 20, 2026Latest source record: Apr 3, 2018 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2009
May 28, 2009
Approved uses
2
Original approval plus efficacy supplements
Registered trials
22
7 Phase 3, 0 recruiting
FAERS reports
969
423 serious, 67 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Jul 28, 2026.
Besifloxacin ophthalmic suspension 0.6% is indicated for the treatment of bacterial conjunctivitis caused by susceptible isolates of the following bacteria: Aerococcus viridans * CDC coryneform group G Corynebacterium pseudodiphtheriticum* Corynebacterium striatum* Haemophilus influenzae Moraxella catarrhalis* Moraxella lacunata* Pseudomonas aeruginosa* Staphylococcus aureus Staphylococcus epidermidis Staphylococcus hominis* Staphylococcus lugdunensis* Staphylococcus warneri* Streptococcus mitis group Streptococcus oralis Streptococcus pneumoniae Streptococcus salivarius * *Efficacy for this organism was studied in fewer than 10 infections. Besifloxacin ophthalmic suspension 0.6% is a quinolone antimicrobial indicated for the treatment of bacterial conjunctivitis caused by susceptible isolates of the following bacteria: Aerococcus viridans*, CDC coryneform group G, Corynebacterium pseudodiphtheriticum*, Corynebacterium striatum*, Haemophilus influenzae, Moraxella catarrhalis*, Moraxella lacunata*, Pseudomonas aeruginosa*, Staphylococcus aureus, Staphylococcus epidermidis, Staphylococcus hominis*, Staphylococcus lugdunensis*, Staphylococcus warneri*, Streptococcus mitis group , Streptococcus oralis, Streptococcus pneumoniae, Streptococcus salivarius* *Efficacy for this organism was studied in fewer than 10 infections. ( 1 )
Mechanism: Besifloxacin is a fluoroquinolone antibacterial [see Microbiology ( 12.4 )] .
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Sep 18, 2012 Supplement 3 · Efficacy LabelLetter
- May 28, 2009 Original approval · Type 1 - New Molecular Entity NovelLabelReviewSummary Review
1 products under this application
- BESIVANCE · BESIFLOXACIN HYDROCHLORIDE EQ 0.6% BASE · SUSPENSION/DROPS, OPHTHALMIC · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Besifloxacin" as an intervention, any sponsor and status, largest first.
- A Study to Investigate the Safety and Efficacy of BOL-303224 in the Treatment of Bacterial ConjunctivitisPivotal-lookingCompleted
Bausch & Lomb IncorporatedIndustry
NCT00348348 · 1,161 participants · Start Jun 2006 · Primary completion Jul 2007
Drug: Besifloxacin; Moxifloxacin solution · For: Acute Bacterial Conjunctivitis
- A Study to Determine if 0.6% ISV-403 is Safe and Effective in the Treatment of Bacterial Conjunctivitis.Pivotal-lookingCompleted
Bausch & Lomb IncorporatedIndustry
NCT00347932 · 957 participants · Start Jun 2006 · Primary completion Nov 2007
Drug: ISV-403; Vehicle · For: Acute Bacterial Conjunctivitis
- Safety of Besivance™ (Besifloxacin Ophthalmic Suspension) 0.6% Compared to VehiclePivotal-lookingCompleted
Bausch & Lomb IncorporatedIndustry
NCT01175590 · 518 participants · Start Jun 2010 · Primary completion Dec 2011
Drug: Besivance; Vehicle · For: Bacterial Conjunctivitis
Sites: Rochester, New York
- Efficacy of Besifloxacin Ophthalmic Suspension in the Treatment of Bacterial ConjunctivitisPivotal-lookingCompleted
Bausch & Lomb IncorporatedIndustry
NCT00972777 · 474 participants · Start Oct 2009 · Primary completion Oct 2010
Drug: Besifloxacin; Vehicle (Placebo) · For: Bacterial Conjunctivitis
Sites: Rochester, New York
- Clinical and Microbial Efficacy of ISV403 in Bacterial ConjunctivitisPivotal-lookingCompleted
Bausch & Lomb IncorporatedIndustry
NCT00622908 · 270 participants · Start Dec 2004 · Primary completion Jun 2005
Drug: ISV-403; Vehicle · For: Bacterial Conjunctivitis
- Clinical and Microbial Efficacy of Besifloxacin Ophthalmic Suspension, 0.6% in the Treatment of Bacterial ConjunctivitisPivotal-lookingTerminated
Bausch & Lomb IncorporatedIndustry
NCT01740388 · 136 participants · Start Feb 2013 · Primary completion Jul 2013
Drug: Besifloxacin; Vehicle · For: Bacterial Conjunctivitis
Sites: Rochester, New York
- Corneal Endothelial Cell Density Changes In Healthy Subjects, When Administered ISV-403 for 5 DaysPivotal-lookingCompleted
Bausch & Lomb IncorporatedIndustry
NCT01120418 · 120 participants · Start May 2007 · Primary completion Oct 2007
Drug: Besifloxacin Ophthalmic Suspension 0.6% · For: Healthy
Sites: Rochester, New York
- Aqueous Absorption and Pharmacokinetics of Besivance Versus VIGAMOX in Patients Undergoing PhacoemulsificationPivotal-lookingCompleted
Frank A. Bucci, Jr., M.D.Academic, hospital or other
NCT01296191 · 120 participants · Start May 2011 · Primary completion Jan 2013
Drug: Moxifloxacin; besifloxacin · For: Cataracts
Sites: Wilkes-Barre, Pennsylvania
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- eye pain104
- vision blurred82
- eye irritation79
- off label use78
- hypersensitivity68
- ocular hyperaemia60
- cardiac disorder50
- chronic kidney disease42
- drug ineffective36
- photophobia36
- impaired healing34
- foreign body sensation in eyes33
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2009 | 16 |
| 2010 | 62 |
| 2011 | 43 |
| 2012 | 44 |
| 2013 | 22 |
| 2014 | 42 |
| 2015 | 70 |
| 2016 | 87 |
| 2017 | 106 |
| 2018 | 103 |
| 2019 | 81 |
| 2020 | 61 |
| 2021 | 53 |
| 2022 | 65 |
| 2023 | 57 |
| 2024 | 36 |
| 2025 | 13 |
| 2026 | 8 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Besivance (Besifloxacin HCl)
2024 spending
$6.8M
Beneficiaries
19,935
30,315 claims
Per beneficiary
$340
$44.02 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $18,027,402 |
| 2021 | $18,032,812 |
| 2022 | $14,250,102 |
| 2023 | $10,644,648 |
| 2024 | $6,786,112 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Besifloxacin Ophthalmic Suspension 0.6% Compared with Gatifloxacin Ophthalmic Solution 0.3% for the Treatment of Bacterial Conjunctivitis in Neonates.
Sanfilippo CM, Allaire CM, DeCory HH · Drugs R D 2017 · Comparative Study, Multicenter Study
- The safety of besifloxacin ophthalmic suspension 0.6 % used three times daily for 7 days in the treatment of bacterial conjunctivitis.
Malhotra R, Ackerman S, Gearinger LS, et al. · Drugs R D 2013 · Multicenter Study, Randomized Controlled Trial
- Clinical and Antibacterial Efficacy and Safety of Besifloxacin Ophthalmic Suspension Compared With Moxifloxacin Ophthalmic Solution.
Garg P, Mathur U, Sony P, et al. · Asia Pac J Ophthalmol (Phila) 2015 · Multicenter Study, Randomized Controlled Trial
- Ocular pharmacokinetics of besifloxacin following topical administration to rabbits, monkeys, and humans.
Proksch JW, Granvil CP, Siou-Mermet R, et al. · J Ocul Pharmacol Ther 2009 · Clinical Trial
- Microbiological etiology and susceptibility of bacterial conjunctivitis isolates from clinical trials with ophthalmic, twice-daily besifloxacin.
Haas W, Gearinger LS, Hesje CK, et al. · Adv Ther 2012 · Randomized Controlled Trial, Research Support, Non-U.S. Gov't
- Aqueous penetration of moxifloxacin 0.5% ophthalmic solution and besifloxacin 0.6% ophthalmic suspension in cataract surgery patients.
Yoshida J, Kim A, Pratzer KA, et al. · J Cataract Refract Surg 2010 · Comparative Study, Randomized Controlled Trial
Sponsor: Bausch and Lomb
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.